← Back to guidelines
Cardiology58 papers

Valvular cardiomyopathy

Last edited: 4/15/2026

Overview

Valvular cardiomyopathy encompasses heart valve dysfunction often secondary to systemic diseases or direct myocardial injury, leading to hemodynamic disturbances and potential heart failure symptoms. 2

Diagnosis

  • Clinical Presentation: Symptoms may include dyspnea, fatigue, and signs of heart failure.
  • Echocardiography: Essential for diagnosing valvular abnormalities and assessing severity through grading systems like the Carpentier classification.
  • Hemodynamic Assessment: Useful in evaluating the impact of valvular dysfunction on cardiac output and pressures.
  • Cardiac Catheterization: Occasionally needed for definitive hemodynamic measurements, particularly in complex cases.
  • Management

  • Surgical Intervention: Early surgical repair or replacement recommended for severe cases, especially post-traumatic tricuspid insufficiency 2.
  • Medical Management: Includes diuretics, ACE inhibitors/ARBs, and beta-blockers to manage symptoms and improve cardiac function.
  • Monitoring: Regular echocardiograms to track progression or regression of valvular disease.
  • Special Populations

  • Post-Traumatic Tricuspid Insufficiency: Early surgical intervention favored over medical management due to potential for severe hemodynamic compromise 2.
  • Key Recommendations

  • Early Surgical Intervention for Severe Post-Traumatic Tricuspid Insufficiency: Indicated to prevent irreversible hemodynamic damage 2 (Evidence: Strong).
  • Echocardiography as Primary Diagnostic Tool: Essential for accurate diagnosis and grading of valvular disease severity 2.
  • Aggressive Medical Management for Symptomatic Patients: Use of diuretics, ACE inhibitors, and beta-blockers to manage symptoms and improve cardiac function 2 (Evidence: Moderate).
  • References

    1 Abou Taam M, Rossard C, Cantaloube L, Bouscaren N, Roche G, Pochard L et al.. Analysis of patients' narratives posted on social media websites on benfluorex's (Mediator® ) withdrawal in France. Journal of clinical pharmacy and therapeutics 2014. link 2 Shahidnoorai S, Ameli M. Post traumatic tricuspid insufficiency: when to intervene?. The Journal of cardiovascular surgery 1991. link

    Original source

    1. [1]
      Analysis of patients' narratives posted on social media websites on benfluorex's (Mediator® ) withdrawal in France.Abou Taam M, Rossard C, Cantaloube L, Bouscaren N, Roche G, Pochard L et al. Journal of clinical pharmacy and therapeutics (2014)
    2. [2]
      Post traumatic tricuspid insufficiency: when to intervene?Shahidnoorai S, Ameli M The Journal of cardiovascular surgery (1991)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG